Tianjin Pharmaceutical Da Ren Tang Group (600329) Stock Overview
Engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
600329 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥43.19 |
| 52 Week High | CN¥50.97 |
| 52 Week Low | CN¥28.53 |
| Beta | 0.78 |
| 1 Month Change | -5.06% |
| 3 Month Change | -7.69% |
| 1 Year Change | 38.70% |
| 3 Year Change | 21.12% |
| 5 Year Change | 139.41% |
| Change since IPO | 208.50% |
Recent News & Updates
Recent updates
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) Subdued P/E Might Signal An Opportunity
Mar 16
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt
Dec 18Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?
Oct 27Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge
Oct 08Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio
Jul 26Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Jul 05Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)
Apr 18Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Mar 18Shareholder Returns
| 600329 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -8.0% | -0.8% | 0.9% |
| 1Y | 38.7% | 16.1% | 28.3% |
Return vs Industry: 600329 exceeded the CN Pharmaceuticals industry which returned 16.1% over the past year.
Return vs Market: 600329 exceeded the CN Market which returned 28.3% over the past year.
Price Volatility
| 600329 volatility | |
|---|---|
| 600329 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 3.1% |
Stable Share Price: 600329 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600329's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,619 | n/a | www.jydrt.com.cn |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamentals Summary
| 600329 fundamental statistics | |
|---|---|
| Market cap | CN¥29.38b |
| Earnings (TTM) | CN¥3.58b |
| Revenue (TTM) | CN¥5.37b |
Is 600329 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600329 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.37b |
| Cost of Revenue | CN¥1.86b |
| Gross Profit | CN¥3.51b |
| Other Expenses | -CN¥70.23m |
| Earnings | CN¥3.58b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 31, 2026
| Earnings per share (EPS) | 4.65 |
| Gross Margin | 65.37% |
| Net Profit Margin | 66.68% |
| Debt/Equity Ratio | 0.2% |
How did 600329 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/16 08:31 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Chengzhi Chen | CGS International |
| Yuan Yuan Sun | Industrial Securities Co. Ltd. |